The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.
About half of patients (n=232; 51.5%) were treated with ATO/ATRA alone, while 86 (19.1%) underwent intensified therapy with chemotherapy in addition to ATO and/or ATRA.
He explains how this in vivo lentiviral vector infusion aims to eliminate traditional manufacturing barriers by shifting the cell engineering process directly into the patient’s body.
William G. Wierda, MD, of the University of Texas MD Anderson Cancer Center, and colleagues, published the findings in Blood.
To date, the initiative has enabled access to the treatment for more than 300 patients across Armenia, Ethiopia, and Nepal, exceeding its original scope by about 150 patients.
The study’s authors, led by Lihua E Budde, MD, PhD, of City of Hope in Duarte, California, published the findings in the Journal of Hematology & Oncology.
From EHA 2026, Dr. Loretta Nastoupil interviews Dr. Georg Lenz on the phase 3 FRONTMIND study, a randomised, double-blind, placebo-controlled study that evaluated tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma.
SOHO Insider is the official media platform of the Society of Hematologic Oncology. The SOHO Insider Editorial Board is comprised of leading hematologists. Learn more about our editorial board and SOHO Insider platforms.
To access the SOHO Career Center click the following link.
